The transparency of the prices of medicines

The entry into force of Law 29/2017 on Public Procurement and the application of Law 19/2013 on transparency, access to public information and good government raises various questions in relation with the publicity that should be given to administrative decisions fixing the maximum ex-factory price for reimbursed medicines in Spain. The authors understand that the rules that govern the price of medicines and competition law allow to question how the rules on transparency should be applied; and that the objectives that such rules aim to achieve may be reached without companies having to renounce to keep some information as confidential.